Medigene AG (VIE:MDG2)

Market Cap	1.03M
Revenue (ttm)	7.45M
Net Income (ttm)	-15.93M
Shares Out	n/a
EPS (ttm)	-1.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0694
Previous Close	0.0680
Day's Range	0.0694 - 0.0746
52-Week Range	0.0606 - 2.1850
Beta	n/a
RSI	47.63
Earnings Date	n/a

About Medigene AG

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develops MDG2011, MDG2021, MDG2012, MDG20XX, and MDG10xx to treat multiple solid tumors. It has a strategic partnership with BioNTech to develop TCRbased immu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 87
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: MDG2

Financial Performance

In 2023, Medigene AG's revenue was 6.03 million, a decrease of -80.69% compared to the previous year's 31.25 million. Losses were -16.18 million, 94.2% more than in 2022.